{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:30:54Z","timestamp":1788546654773,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Western Pacific"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.lanwpc.2024.101122","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T13:48:39Z","timestamp":1718632119000},"page":"101122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanrong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejie","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shucai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanwpc.2024.101122_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.lanwpc.2024.101122_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2024.101122_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.lanwpc.2024.101122_bib10","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib11","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanwpc.2024.101122_bib12","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s11136-017-1574-9","article-title":"The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries","volume":"26","author":"Kleijnen","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lanwpc.2024.101122_bib13","first-page":"188","article-title":"Payer perceptions on the use of patient-reported outcomes in oncology decision making","volume":"28","author":"Oderda","year":"2022","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.lanwpc.2024.101122_bib14","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000244","article-title":"An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients","volume":"9","author":"Gralla","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lanwpc.2024.101122_bib16","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jtho.2020.01.010","article-title":"Safety, clinical activity, and pharmacokinetics of alflutinib (AST2818) in patients with advanced NSCLC with EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jtho.2022.07.1143","article-title":"Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study","volume":"17","author":"Shi","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.lanwpc.2024.101122_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0959-8049(94)90535-5","article-title":"The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC study group on quality of life","volume":"30A","author":"Bergman","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lanwpc.2024.101122_bib20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/07357900701781788","article-title":"Validation of the simplified Chinese version of the quality of life instrument EORTC QLQ-LC43 for patients with lung cancer","volume":"26","author":"Wan","year":"2008","journal-title":"Cancer Invest"},{"key":"10.1016\/j.lanwpc.2024.101122_bib21","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib23","series-title":"EORTC quality of life group","article-title":"EORTC QLQ-C30 reference values manual","author":"Scott","year":"2008"},{"key":"10.1016\/j.lanwpc.2024.101122_bib24","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s11136-006-0040-x","article-title":"Comparing translations of the EORTC QLQ-C30 using differential item functioning analyses","volume":"15","author":"Scott","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lanwpc.2024.101122_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-006-9120-1","article-title":"The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30","volume":"16","author":"Scott","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.lanwpc.2024.101122_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2019.11.006","article-title":"Patient-reported outcomes from FLAURA: osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer","volume":"125","author":"Leighl","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lanwpc.2024.101122_bib27","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2022.11.004","article-title":"Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer","volume":"174","author":"Mazieres","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lanwpc.2024.101122_bib28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib29","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(19)30801-0","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib30","article-title":"9P First-line (1L) osimertinib (osi) \u00b1 platinum-pemetrexed in EGFRm advanced NSCLC: FLAURA2 patient-reported outcomes (PROs)","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lanwpc.2024.101122_bib31","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","article-title":"Patient-reported symptoms and impact of treatment with osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial","volume":"36","author":"Lee","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.lanwpc.2024.101122_bib33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"}],"container-title":["The Lancet Regional Health - Western Pacific"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524001160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666606524001160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T20:58:14Z","timestamp":1724705894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666606524001160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":33,"alternative-id":["S2666606524001160"],"URL":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101122","relation":{},"ISSN":["2666-6065"],"issn-type":[{"value":"2666-6065","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Western Pacific","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101122","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101122"}}